Jennifer Lachey - May 11, 2021 Form 4 Insider Report for Keros Therapeutics, Inc. (KROS)

Role
Chief Scientific Officer
Signature
/s/ Keith Regnante, Attorney-in-Fact
Stock symbol
KROS
Transactions as of
May 11, 2021
Transactions value $
-$130,871
Form type
4
Date filed
5/13/2021, 04:36 PM
Next filing
Jun 15, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KROS Common Stock Options Exercise $795 +2.65K +3.72% $0.30* 73.8K May 11, 2021 Direct
transaction KROS Common Stock Sale -$133K -2.65K -3.59% $50.00 71.2K May 11, 2021 Direct F1
transaction KROS Common Stock Options Exercise $684 +6.22K +8.74% $0.11* 77.4K May 13, 2021 Direct
transaction KROS Common Stock Options Exercise $150 +500 +0.65% $0.30* 77.9K May 13, 2021 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KROS Employee Stock Option (right to buy) Options Exercise $0 -2.65K -1.96% $0.00 132K May 11, 2021 Common Stock 2.65K $0.30 Direct F2
transaction KROS Employee Stock Option (right to buy) Options Exercise $0 -6.22K -100% $0.00* 0 May 13, 2021 Common Stock 6.22K $0.11 Direct F2
transaction KROS Employee Stock Option (right to buy) Options Exercise $0 -500 -6.03% $0.00 7.79K May 13, 2021 Common Stock 500 $0.30 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
F2 Immediately exercisable.
F3 One-twelfth (1/12th) of the shares subject to the option vested or shall vest in equal quarterly installments commencing on March 18, 2018, subject to the Reporting Person continuing to provide service through each such date.